Free Trial
NASDAQ:CTKB

Cytek Biosciences (CTKB) Stock Price, News & Analysis

Cytek Biosciences logo
$3.79 -0.24 (-5.96%)
Closing price 08/11/2025 04:00 PM Eastern
Extended Trading
$3.76 -0.03 (-0.79%)
As of 08/11/2025 07:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Cytek Biosciences Stock (NASDAQ:CTKB)

Key Stats

Today's Range
$3.68
$4.02
50-Day Range
$2.85
$4.11
52-Week Range
$2.37
$7.63
Volume
1.67 million shs
Average Volume
1.10 million shs
Market Capitalization
$482.16 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.60
Consensus Rating
Hold

Company Overview

Cytek Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
51st Percentile Overall Score

CTKB MarketRank™: 

Cytek Biosciences scored higher than 51% of companies evaluated by MarketBeat, and ranked 1048th out of 1,853 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Cytek Biosciences has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 2 buy ratings, 2 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Cytek Biosciences has only been the subject of 1 research reports in the past 90 days.

  • Read more about Cytek Biosciences' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cytek Biosciences is -75.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cytek Biosciences is -75.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Cytek Biosciences has a P/B Ratio of 1.23. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    4.93% of the float of Cytek Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Cytek Biosciences has a short interest ratio ("days to cover") of 5.
  • Change versus previous month

    Short interest in Cytek Biosciences has recently increased by 19.20%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Cytek Biosciences does not currently pay a dividend.

  • Dividend Growth

    Cytek Biosciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.93% of the float of Cytek Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Cytek Biosciences has a short interest ratio ("days to cover") of 5.
  • Change versus previous month

    Short interest in Cytek Biosciences has recently increased by 19.20%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Cytek Biosciences has a news sentiment score of 0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 10 news articles for Cytek Biosciences this week, compared to 3 articles on an average week.
  • Search Interest

    2 people have searched for CTKB on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Cytek Biosciences to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Cytek Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $194,600.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    10.33% of the stock of Cytek Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    69.46% of the stock of Cytek Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Cytek Biosciences' insider trading history.
Receive CTKB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytek Biosciences and its competitors with MarketBeat's FREE daily newsletter.

CTKB Stock News Headlines

Trump’s national nightmare is here
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.
Cytek Biosciences (CTKB) to Release Earnings on Wednesday
See More Headlines

CTKB Stock Analysis - Frequently Asked Questions

Cytek Biosciences' stock was trading at $6.49 at the beginning of the year. Since then, CTKB shares have decreased by 41.6% and is now trading at $3.79.

Cytek Biosciences, Inc. (NASDAQ:CTKB) released its quarterly earnings results on Thursday, May, 8th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by $0.05. The business earned $41.46 million during the quarter, compared to analyst estimates of $43.18 million. Cytek Biosciences had a negative net margin of 3.27% and a negative trailing twelve-month return on equity of 1.66%.
Read the conference call transcript
.

Cytek Biosciences' board authorized a stock repurchase program on Monday, December 30th 2024, which authorizes the company to buy back $50,000,000 in shares, according to EventVestor. This means that the company could repurchase up to 5.9% of its stock through open market purchases. Stock buyback programs are often a sign that the company's leadership believes its stock is undervalued.

Cytek Biosciences (CTKB) raised $248 million in an initial public offering (IPO) on Friday, July 23rd 2021. The company issued 14,564,635 shares at $16.00-$18.00 per share.

Top institutional investors of Cytek Biosciences include Geode Capital Management LLC (2.16%), Connor Clark & Lunn Investment Management Ltd. (0.25%), Public Employees Retirement System of Ohio (0.05%) and State of Alaska Department of Revenue (0.05%). Insiders that own company stock include Ming Yan, Wenbin Jiang, Patrik Jeanmonod, William D Mccombe and Jack Ball.
View institutional ownership trends
.

Shares of CTKB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cytek Biosciences investors own include American Water Works (AWK), Waste Connections (WCN), DiamondRock Hospitality (DRH), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), AU Optronics (AUOTY) and Humana (HUM).

Company Calendar

Last Earnings
5/08/2025
Today
8/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Measuring And Control Equipment
Current Symbol
NASDAQ:CTKB
CIK
1831915
Fax
N/A
Employees
500
Year Founded
N/A

Price Target and Rating

High Price Target
$8.00
Low Price Target
$3.00
Potential Upside/Downside
+47.8%
Consensus Rating
Hold
Rating Score (0-4)
2.20
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.05)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$6.02 million
Net Margins
-3.27%
Pretax Margin
-3.86%
Return on Equity
-1.66%
Return on Assets
-1.30%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.22
Quick Ratio
4.55

Sales & Book Value

Annual Sales
$196.04 million
Price / Sales
2.46
Cash Flow
$0.03 per share
Price / Cash Flow
116.13
Book Value
$3.07 per share
Price / Book
1.23

Miscellaneous

Outstanding Shares
127,224,000
Free Float
114,082,000
Market Cap
$482.18 million
Optionable
Optionable
Beta
1.34

Social Links

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:CTKB) was last updated on 8/12/2025 by MarketBeat.com Staff
From Our Partners